Cell types – cell lines used with LRC-TriCEPS

Living cell types used with LRC-TriCEPS

Dualsystems Biotech AG has used the LRC-TriCEPS Technology with a large number of different cell lines, primary cells and tissue to identify the targets and off targets of different types of biologics – peptides, proteins, antibodies, antibody drug conjugates – and viruses. The list is not complete and constantly growing:

Human cell lines:

  • Human embryonic kidney cells line
  • Human mammary gland cancer cell line
  • Human breast cancer cell line
  • Human T lymphocyte cell line
  • Human cutaneous T lymphocyte cell line
  • Human prostatic adenocarcinoma cell line
  • Human prostate cancer cell line
  • Human pulmonary mucoepidermoid carcinoma cell line
  • Human Caucasian bronchioalveolar carcinoma cell line
  • Human leukemia cell line
  • Human osteosarcoma cell line
  • Human neuroblastoma cell line
  • Human hepatoma cell line
  • Human retinal epithelium cell line
  • Human glioblastoma cell line

Rodent cell lines:

  • Rat hepatoma cell line

Insect cell lines:

  • Drosophila cell line

Primary cells:

  • Human primary T-cells


Are you looking for the targets of your ligand – peptide, protein, antibody, and virus – that are relevant in the living organism?

Call us or fill in the contactform on the right side of the website or use the an email and we will get back to explore how far the LRC-TriCEPS™ technology can go to answer your questions.

Phone: +41 44 738 50 00



Customers Testimonials – LRC-TriCEPS Service

Please see below the testimonials from our customers who have used  the LRC-TriCEPSTM technology –  CaptiRec – in collaboration with Dualsystems Biotech AG.

La BioMed

PUBLICATION:  Li Z, Zeppa JJ, Hancock MA, McCormick JK, Doherty TM, Hendy GN, and Madrenas J.  Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells. J Immunol. 2018; 200: 1471-1479.


The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics.  However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays.   We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates.

(Quim) Madrenas, MD, PhD, FCAHS
Chief Scientific Officer
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center



Important new receptors for Follicum’s lead candidate FOL-005 in hair follicle cells identified.

See press release January 18, 2018 (PDF)

Igenica Biotherapeutics

“Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.

Update 2017: Pierre Fabre Pharmaceuticals acquires promising assets from Igenica Biotherapeutics in the field of immuno-oncology (PDF)


Dr. Edward van der Horst,
Senior Director, Preclinical Development
Igenica Biotherapeutics

QIMR Berghofer Medical Research Institute, Australien

“With the help of the team at Dualsystems we confirmed a potential receptor which has lead to a Nature paper submission and successful funding of a research grant. The LRC-TriCEPS experiment was straightforward and the process was cost effective. We look forward to using TriCEPS in the future.”

QIMR Berghofer Medical Research Institute Logo

Anita Burgess | PhD
Hepatic Fibrosis Group
QIMR Berghofer Medical Research Institute, Australia

University of Miami, Miller School of Medicine

We are very pleased with the experience and interaction on very high professional level with Dualsystems Biotech. As a result of such collaboration the new receptor MUC5B was identified in human chondrosarcoma cells for the first time for antiproliferative neuropeptide PRP-1. This led to publication of the major manuscript and, most importantly, it opens up many interesting clinical and basic science possibilities for further exploration of this peptides mode of action. I would recommend this reputable company to any researcher interested in the search for new receptor candidates. The Triceps technology is so innovative in its design, which captures receptor candidates thus  eliminating, months and months of otherwise extra tedious receptor search procedures.

I would like to thank once again the company and, particularly, Dr Helbling for his attention and collaboration.

Dr Karina Galoian
Research associate professor
University of Miami, Miller School of Medicine
Department of Orthopedic surgery
Miami, Florida, USA

Münster University Hospital (UKM)

“Dualsystems Biotech’s approach to receptor identification with the TriCEPS reagent gave us a powerful platform with great support for a successful and fast data generation, when conventional approaches had previously failed.”

Dr. rer. nat. Martin Herold
Working group from Prof. Dr. med. Luisa Klotz
Münster University Hospital (UKM), Germany

University of Manitoba

“Every aspect of our experience with Dualsystems Biotech was outstanding.  They provided excellent customer service and technical support throughout the entire process.  Their LRC-TriCEPS technology allowed us to identify several new candidate receptors for our protein of interest in rat primary neurons, and this has created new and exciting avenues for our research.”


Sari S. Hannila, PhD, Associate Professor, Department of Human Anatomy and Cell Science
Associate Member, Spinal Cord Research Centre, Max Rady College of Medicine, Rady Faculty of Health Sciences
University of Manitoba

The Rockefeller University

“We are very pleased with the work product of Dualsystems Biotech. The TriCEPS reagent allowed us to identify a novel ligand-extracellular matrix protein receptor interaction, which was not possible using traditional techniques. The Dualsystems team were very helpful in tailoring the experimental conditions to fit our biological question.”

Manish Ponda, M.D., M.S., Assistant Professor of Clinical Investigation
The Rockefeller University

Medizinische Hochschule Hannover

With the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify receptor candidates for our peptide with renoprotective properties in kidney injury.


Dr. rer. nat. Inga Sörensen-Zender, Postdoc
Medizinische Hochschule Hannover

East Tennessee State University

Jonathan M Peterson, April 2016, The FASEB Journal, vol. 30 no. 1 Supplement 1249.2 Identification of cell surface receptors for the novel adipokine CTRP3

For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.

Logo East Tennessee State University

Jonathan M Peterson
Assistant Professor
East Tennessee State University

CEDOC – Centro de Estudos de Doenças Crónicas

New publication October 2015 in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson M. Gontijo, Principal Investigator at CEDOC (Centro de Estudos de Doenças Crónicas)

« The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified »


Alisson M. Gontijo,
Principal Investigator at CEDOC
Centro de Estudos de Doenças Crónicas

University of California San Francisco (UCSF)

“We have been trying to identify a receptor that has been sought after for nearly 30 years by laboratories across the globe. Thanks to Dualsystems service CaptiRec (LRC-TriCEPS), we now have a strong candidate receptor.”

Logo University of Califonia SF

De’Broski R. Herbert Ph.D.
Assistant Professor in Residence
University of California San Francisco (UCSF)

Washington University School of Medicine

“Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems”

Logo Washington_University

Fumihiko Urano, MD, PhD
Samuel E. Schechter Professor of Medicine
Washington University School of Medicine


Target Identification publication at the EBR magazine April 2015

Target-identificationDo you need target identification of your ligand? Ligand-receptor capture (LRC-TriCEPSTM) a new approach to find the targets in the cell membrane on the living cells.

Read the article at the EBR magazine (site 25) for more details or the pdf.

EBR Magazin-April-15-Dualsystems-Ligand-receptor